Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 14/20 | 0.64 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.64 |
| ▸ | BRD4 | O60885 | 12/20 | 0.63 |
| ▸ | TAF1 | P21675 | 2/20 | 0.63 |
| ▸ | BRDT | Q58F21 | 7/20 | 0.62 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.62 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.62 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.62 |
| ▸ | FES | P07332 | 2/20 | 0.62 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.62 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.62 |
| ▸ | CLK2 | P49760 | 2/20 | 0.62 |
| ▸ | NEK2 | P51955 | 2/20 | 0.62 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.62 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.62 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.62 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.62 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.62 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781640 | 0.92 | AURKA (0.69) | PLK1PLK3BRD4TAF1BRDT | |
| SCHEMBL1780819 | 0.92 | PLK1 (0.59) | PLK1PLK3BRD4TAF1BRDT | |
| SCHEMBL1782281 | 0.89 | TTK (0.54) | PLK1PLK3BRD4TAF1BRDT | |
| SCHEMBL5921305 | 0.87 | PLK1 (0.64) | PLK1PLK3BRD4TAF1BRDT | |
| SCHEMBL1781821 | 0.85 | TTK (0.59) | PLK1PLK3BRD4TAF1BRDT | |
| SCHEMBL1781344 | 0.83 | TTK (0.84) | PLK1PLK3BRD4EGFRCAMK2D | |
| SCHEMBL1781503 | 0.83 | CDK4 (0.65) | DAPK3EGFRDCLK1CDK4TTK | |
| SCHEMBL1781666 | 0.82 | TTK (0.60) | PLK1PLK3BRD4TAF1BRDT | |
| SCHEMBL1782435 | 0.82 | TTK (0.58) | PLK1PLK3BRD4BRDTPRKD3 | |
| SCHEMBL5921473 | 0.82 | AURKA (0.65) | PLK1PLK3BRD4TAF1BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | PLK1 7/4885PLK3 387/4885BRD4 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.